The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Boston Scientific has reported Q2 revenues of around $5.4bn, indicative of a 7.5% year-over-year (YoY) rise, yet has elected to trim its full-year outlook.

The lion's share of Boston's revenues came from its cardiovascular segment at around $3.6bn, indicative of an 8.3% YoY uplift and driven by the ongoing adoption of its FARAPULSE pulsed field ablation (PFA) system.

Meanwhile, Boston's medsurg business generated $1.8bn. Endoscopy contributed $793m, while urology and neuromodulation yielded $684m and $341m, respectively.

Following the release of its Q1 financials in April, the medtech giant anticipated 2026 revenue growth between 7%-8.5% with earnings mooted to fall in the $3.34 to $3.41 per share range. Following its Q2 results, however, Boston now expects its 2026 earnings per share (EPS) to fall between $3.28 and $3.32, with sales growth of approximately 5.5%-6.5%.

The tempered 2026 outlook is likely due in part to Boston's planned global restructuring programme that the company said is being initiated in an effort to drive "sustained cost efficiencies" and support continued growth across its business operations.

The plan, which is expected to be complete by the end of 2029, was publicly disclosed in a Form 8-K filing with the US Securities and Exchange Commission (SEC) on 27 July. Boston anticipates that the undertaking will cost between $700m and $800m, of which approximately $600m to $700m is expected to result in future cash outlays, as well as reducing annual pre-tax expenses by approximately $500m as the programme's benefits are realised.

Boston released its Q2 financials ahead of market open, with the company's share price on the New York Stock Exchange (NYSE) falling by over 5% to $42.67 at the start of trading on 29 July versus a previous close at $46.06. Boston Scientific has a market cap of $66.25bn.

Boston's CEO Mike Mahoney said: "We are focused on disciplined execution and prioritising investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians."

"Boston Scientific reports positive Q2 results yet opts to trim 2026 outlook" was originally created and published by Medical Device Network, a GlobalData owned brand.